As Americans debate the rising cost of prescription drugs and the safety of global supply chains, one overlooked threat is quietly gaining ground: China is reshaping the rules of global drug regulation and using them as a tool of influence.

Beijing’s expanding footprint in low- and middle-income countries through its Belt and Road Initiative now includes not just roads, ports and power plants — it also includes the regulatory systems that govern food and medicine. In dozens of countries, China is training regulators, rewriting technical standards and providing equipment and infrastructure all aligned with its own state-centered model of governance.

This isn’t just about pharmaceuticals. It’s about geopolitical leverage, and the United States needs to act.

For decades, the U.S. has led e

See Full Page